Arvinas to Present Data at the 2016 AACR Annual Meeting

NEW HAVEN, Conn., April 14, 2016  Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced that it will present two posters at the 2016 Annual Meeting of the American Association for Cancer Research ("AACR") in New Orleans, Louisiana, being held from April 16^th to the 20^th, 2016. 

The poster presentations further expand on the utility of Arvinas' BRD4 degraders in ovarian cancer and acute myeloid leukemia ("AML").  The presentations are derived from work conducted at Arvinas and at Arvinas' collaborators at The University of Texas MD Anderson Cancer Center. In addition, Arvinas recently presented BRD4 degraders in preclinical models of acute leukemias, multiple myeloma and lymphoma at the 57^th Annual Meeting of the American Society of Hematology in December 2015. 

Poster presentation details:

The Arvinas poster will also be available on the Arvinas web site www.arvinas.com on April 20^th in the publications section.

About Arvinas
Arvinas is a pharmaceutical company focused on developing new small molecules aimed at degrading disease-causing cellular proteins. We are translating these innovative protein degradation approaches into novel drugs for the treatment of cancer and other diseases. Many diseases are a result of "rogue," uncontrolled proteins, whose absence could bring great clinical benefit to patients. To address these pathological intracellular proteins, Arvinas is developing a new drug paradigm based on the elimination of these proteins. Our innovative protein degradation technology uses small molecule drugs to "tag" specific proteins to be degraded by the ubiquitin/proteasome system (UPS), which is responsible for the normal turnover of most proteins within the cell.

Based on groundbreaking research conducted at Yale University by our Founder and Chief Scientific Advisor, Craig Crews, PhD, Arvinas has developed a platform technology to induce the loss of intracellular proteins: Proteolysis-Targeting Chimera (PROTAC). The ability of PROTAC-based drugs to induce protein degradation (instead of protein inhibition) offers the advantage of potentially targeting "undruggable" as well as "druggable" elements of the proteome. This greatly expands our ability to create drugs for many new, previously unapproachable targets. For more information, visit www.arvinas.com.

CONTACT:
Arvinas Media Contact
Carolyn Hawley
[email protected]
619-849-5382

SOURCE Arvinas